Tag: type 2 diabetes

October 29, 2019

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Medical Inc. (CSE:PREV,  OTCQB:PRVCF, FSE:18H) (the “Company” or “PreveCeutical”), is pleased to announce the successful completion of the design, synthesis and...
October 7, 2019

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

PreveCeutical Medical Inc. is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian...
September 23, 2019

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Medical Inc. (CSE:PREV, OTCQB: PRVCF, FSE:18H), is pleased to provide an update on its dual gene therapy program.
September 3, 2019

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant...
August 6, 2019

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

PreveCeutical Medical Inc. (CSE: PREV) grants Asterion option to purchase up to a 51% Interest in Sol-Gel Intellectual Property
June 21, 2019

PreveCeutical Announces Appointment of New Directors

PreveCeutical Medical Inc. (CSE:PREV), is pleased to announce the appointments of Keith Anderson and Mark Lotz to the board of...
June 17, 2019

PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide positive results from...